Oppenheimer Holdings, Inc. reaffirmed their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a research report sent to investors on Friday morning. Oppenheimer Holdings, Inc. currently has a $60.00 target price on the health services provider’s stock.

A number of other analysts have also recently commented on AMED. BidaskClub cut shares of Amedisys from a hold rating to a sell rating in a research note on Saturday, August 5th. Bank of America Corporation assumed coverage on shares of Amedisys in a research note on Monday, August 21st. They issued a neutral rating and a $55.00 price target for the company. Royal Bank Of Canada reiterated a hold rating and issued a $56.00 price target on shares of Amedisys in a research note on Monday, June 5th. Finally, Mizuho cut shares of Amedisys from a buy rating to a neutral rating and set a $50.00 price target for the company. in a research note on Wednesday, July 26th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $56.44.

Amedisys (NASDAQ:AMED) opened at 51.90 on Friday. The company has a market cap of $1.76 billion, a P/E ratio of 44.36 and a beta of 0.84. Amedisys has a one year low of $34.58 and a one year high of $65.91. The company has a 50-day moving average of $50.17 and a 200 day moving average of $54.94.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The business had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. Equities research analysts predict that Amedisys will post $2.21 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amedisys’ (AMED) “Buy” Rating Reiterated at Oppenheimer Holdings, Inc.” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/19/amedisys-amed-buy-rating-reiterated-at-oppenheimer-holdings-inc.html.

In other news, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the sale, the insider now owns 10,488 shares in the company, valued at approximately $524,400. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bruce D. Perkins bought 2,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $46.60 per share, with a total value of $93,200.00. Following the purchase, the director now owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Company insiders own 2.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Amedisys during the 2nd quarter worth about $591,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Amedisys during the 2nd quarter worth about $380,000. Castleark Management LLC acquired a new stake in shares of Amedisys during the 2nd quarter worth about $3,674,000. The Manufacturers Life Insurance Company lifted its stake in shares of Amedisys by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,348 shares of the health services provider’s stock worth $1,404,000 after buying an additional 410 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Amedisys by 3.9% during the 2nd quarter. State Street Corp now owns 723,786 shares of the health services provider’s stock worth $45,461,000 after buying an additional 26,888 shares during the last quarter. Institutional investors own 96.55% of the company’s stock.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.